Co-existence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1772, Issue 10, 2007, Pages 1134-1142

  He, Lizhi ^a,b   Fan, Catherine ^a,b   Gillis, Aubrey ^a,b   Feng, Xinchang ^a,b   Sanatani, Michael ^a   Hotte, Sebastien ^a   Kapoor, Anil ^a,b   Tang, Damu ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Akt; PTEN; Renal Cell Carcinoma (RCC)

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; HUMAN; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; ENZYME ACTIVATION; HUMANS; KIDNEY NEOPLASMS; MICE; PHOSPHATIDYLINOSITOL PHOSPHATES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE;

MUS;

EID: 36549031293     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2007.07.001     Document Type: Article

References (41)

1. Meloni-Ehrig A.M. Renal cancer: cytogenetic and molecular genetic aspects. Am. J. Med. Genet. 115 (2002) 164-172
2. Karumanchi S.A., Merchan J., and Sukhatme V.P. Renal cancer: molecular mechanisms and newer therapeutic options. Curr. Opin. Nephrol. Hypertens. 11 (2002) 37-42
3. Osaki M., Oshimura M., and Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9 (2004) 667-676
4. Linehan W.M., and Zbar B. Focus on kidney cancer. Cancer Cell 6 (2004) 223-228
5. Mazure N.M., Chen E.Y., Laderoute K.R., and Giaccia A.J. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90 (1997) 3322-3331
6. Blancher C., Moore J.W., Robertson N., and Harris A.J. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res. 61 (2001) 7349-7355
7. Hay N., and Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 18 (2004) 1926-1945
8. Linehan W.M., Vasselli J., Srinivasan R., Walther M.M., Merino M., Choyke P., Vocke C., Schmidt L., Isaacs J.S., Glenn G., Toro J., Zbar B., Bottaro D., and Neckers L. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin. Cancer Res. 10 (2004) 6282S-6289S
9. Cantley L.C., and Neel N.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 4240-4245
10. Besson A., Robbins S.M., and Yong V.W. PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Eur. J. Biochem. 263 (1999) 605-611
11. Paramio J.M., Navarro M., Segrelles C., Gomez-Casero E., and Jorcano J.L. PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein. Oncogene 18 (1999) 7462-7468
12. Samuels Y., and Ericson K. Oncogenic PI3K and its role in cancer. Curr. Opin. Oncol. 18 (2006) 77-82
13. Saal L.H., Holm K., Maurer M., Memeo L., Su T., Wang X., Yu J.S., Malmstrom P.O., Mansukhani M., Enoksson J., Hibshoosh H., Borge A., and Parsons R. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 65 (2005) 2554-2559
14. Suzuki A., de la Pompa J.L., Stambolic V., Elia A.J., Sasaki T., del B.B., Ho A., Wakeham A., Itie A., Khoo W., Fukumoto M., and Mak T.W. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8 (1998) 1169-1178
15. Chen M.L., Xu P.Z., Peng X.D., Chen W.S., Guzman G., Yang X., Di Cristofano A., Pandolfi P.P., and Hay N. The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev. 20 (2006) 1569-1574
16. Sukosd F., Digon B., Fischer J., Pietsch T., and Kovacs G. Allelic loss at 10q23.3 but lack of mutation of PTEN/MMAC1 in chromophobe renal cell carcinoma. Cancer Genet. Cytogenet. 128 (2001) 161-163
17. Brenner W., Farber G., Herget T., Lehr H.A., Hengstler J.G., and Thuroff J.W. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int. J. Cancer 99 (2002) 53-57
18. Lee S.J., Kim S.H., Kim B.Y., Lee C.M., and Park S.C. Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth. J. Surg. Oncol. 84 (2003) 166-172
19. Velickovic M., Delahunt B., McIver B., and Grebe S.K. Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis. Mod. Pathol. 15 (2002) 479-485
20. Tang D., Okada H., Ruland J., Liu L., Stambolic V., Mak T.W., and Ingrama J. Akt is activated in response to an apoptotic signal. J. Biol. Chem. 276 (2001) 30461-30466
21. Brazil D.P., Yang Z.Z., and Hemmings B.A. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem. Sci. 29 (2004) 233-242
22. Horiguchi A., Oya M., Uchida A., Marumo K., and Murai M. Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. J. Urol. 169 (2003) 710-713
23. Hariharan I.K., and Bilder D. Regulation of Imaginal Disc Growth by Tumor-Suppressor Genes in Drosophila. Annu. Rev. Genet. 40 (2006) 335-361
24. Stocker H., Andjelkovic M., Oldham S., Laffargue M., Wymann M.P., Hemmings B.A., and Hafen E. Living with lethal PIP3 levels: viability of flies lacking PTEN restored by a PH domain mutation in Akt/PKB. Science 295 (2002) 2088-2091
25. Di Cristofano A., Pesce B., Cordon-Cardo C., and Pandolfi P.P. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19 (1998) 348-355
26. Freeman D., Lesche R., Kertesz N., Wang S., Li G., Gao J., Groszer M., Martinez-Diaz H., Rozengurt N., Thomas G., Liu X., and Wu H. Genetic background controls tumor development in PTEN-deficient mice. Cancer Res. 66 (2006) 6492-6496
27. Podsypanina K., Ellenson L.H., Nemes A., Gu J., Tamura M., Yamada K.M., Cordon-Cardo C., Catoretti G., Fisher P.E., and Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 1563-1568
28. Stambolic V., Tsao M.S., Macpherson D., Suzuki A., Chapman W.B., and Mak T.W. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res. 60 (2000) 3605-3611
29. Suzuki A., de la Pompa J.L., Stambolic V., Elia A.J., Sasaki T., del Barco Barrantes I., Ho A., Wakeham A., Itie A., Khoo W., Fukumoto M., and Mak T.W. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8 (1998) 1169-1178
30. Cully M., You H., Levine A.J., and Mak T.W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev., Cancer 6 (2006) 184-192
31. Hara S., Oya M., Mizuno R., Horiguchi A., Marumo K., and Murai M. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann. Oncol. 16 (2005) 928-933
32. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
33. Li D.M., and Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res. 57 (1997) 2124-2129
34. Whang Y.E., Wu X., Suzuki H., Reiter R.E., Tran C., Vessella R.L., Said J.W., Isaacs W.B., and Sawyers C.J. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 5246-5250
35. Das S., Dixon J.E., and Cho W. Membrane-binding and activation mechanism of PTEN. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 7491-7496
36. Duerr E.M., Rollbrocker B., Hayashi Y., Peters N., Meyer-Puttlitz B., Louis D.N., Schramm J., Wiestler O.D., Parsons R., Eng C., and von Deimling A. PTEN mutations in gliomas and glioneuronal tumors. Oncogene 16 (1998) 2259-2264
37. Walker S.M., Leslie N.R., Perera N.M., Batty I.H., and Downes C.P. The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif. Biochem. J. 379 (2004) 301-307
38. Lee J.O., Yang H., Georgescu M.M., Di Cristofano A., Maehama T., Shi Y., Dixon J., Pandolfi P., and Pavletich N.P. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 99 (1999) 323-334
39. Salmeen A., and Barford D. Functions and mechanisms of redox regulation of cystein-based phosphatase. Antioxid. Redox Signal. 7 (2005) 560-577
40. Kim R.H., Peters M., Jang Y., Shi W., Pintilie M., Fletcher G.C., DeLuca C., Liepa J., Zhou L., Snow B., Binari R.C., Manoukian A.S., Bray M.R., Liu F.F., Tsao M.S., and Mak T.W. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 7 (2005) 263-273
41. Kondo K., Yao M., Kobayashi K., Ota S., Yoshida M., Kaneko S., Baba M., Sakai N., Kishida T., Kawakami S., Uemura H., Nagashima Y., Nakatani Y., and Hosaka M. PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines. Int. J. Cancer 91 (2001) 219-224